The Impact of the Amendment of the Korean National Health Insurance Reimbursement Criteria for Anti-tumor Necrosis Factor-α Agents on Treatment Pattern, Clinical Response and Persistence in Patients With Rheumatoid Arthritis-Reference-Cited by-同舟云学术

The Impact of the Amendment of the Korean National Health Insurance Reimbursement Criteria for Anti-tumor Necrosis Factor-α Agents on Treatment Pattern, Clinical Response and Persistence in Patients With Rheumatoid Arthritis

Published:2020-07-01 Issue:3 Volume:27 Page:159-167
ISSN:2093-940X
Container-title:Journal of Rheumatic Diseases
language:en
Short-container-title:J Rheum Dis

Author:

Kim Yunkyung¹,Kim Geun-Tae¹,Suh Young Sun²,Kim Hyun-Ok²,Lee Han-Na³⁴,Lee Seung-Geun³⁴^ORCID

Affiliation:

1. Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea

2. Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Gyeongsang National University Changwon Hospital, Changwon, Korea

3. Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea

4. Biomedical Research Institute, Pusan National University Hospital, Busan, Korea

Funder

Pusan National University Hospital

Publisher

Korean College of Rheumatology

Link

http://pdf.medrang.co.kr/JRD/2020/027/JRD027-03-05.pdf

Reference31 articles.

1. 20 years of experience with tumour necrosis factor inhibitors: what have we learned?

2. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

4. Barriers to accessing biologic treatment for rheumatoid arthritis in Greece: the unseen impact of the fiscal crisis—the Health Outcomes Patient Environment (HOPE) study